Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 2,059 of 2,218.
    EudraCT Number: 2018-001616-30 Sponsor Protocol Number: CORT125134-452 Start Date*: 2018-07-09
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
    Medical condition: Endogenous Cushing Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) BG (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001217-15 Sponsor Protocol Number: 85/04/04 Start Date*: 2004-09-16
    Sponsor Name:Lassila Riitta
    Full Title: PRO-FEIBA. Asetelma on selkeä etenevä satunnaistettu kaksisuuntainen tutkimus aktivoitujen hyytymistekijöiden (aPCC, activated prothrombin complex concentrate) vaikutuksesta vaikeaa A hemofiliaa sa...
    Medical condition: A-hemofilia
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006234-16 Sponsor Protocol Number: INT003 Start Date*: 2012-03-27
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refra...
    Medical condition: Patients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004535-24 Sponsor Protocol Number: RLY-4008-101 Start Date*: 2021-07-07
    Sponsor Name:Relay Therapeutics, Inc.
    Full Title: A First-in-Human Study of Highly Selective FGFR2 inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and other Advanced Solid Tumors
    Medical condition: Unresectable or metastatic cholangiocarcinoma (CCA), other advanced solid tumors with an FGFR2-alteration or other potential FGFR2-dependent tumors
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008595 Cholangiocarcinoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014735 Endometrial cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005788-34 Sponsor Protocol Number: NL79578.100.21 Start Date*: 2022-03-31
    Sponsor Name:St. Antonius Hospital
    Full Title: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect
    Medical condition: Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002134-14 Sponsor Protocol Number: 1.0 Start Date*: 2022-09-02
    Sponsor Name:Catharina Hospital Eindhoven
    Full Title: Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study
    Medical condition: Patients with peritoneal carcinomatosis of colorectal origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006367-26 Sponsor Protocol Number: IGTRegs Start Date*: 2023-01-03
    Sponsor Name:Πανεπιστήμιο Πατρών
    Full Title: Phase I / II study of HLA-G + induced T-regulatory cells (iG-Tregs) in patients after allogeneic hematopoietic stem cell transplantation from HLA compatible sibling / donor.
    Medical condition: Adopt immunotherapy in adult patients undergoing hematopoietic stem cell (HSCT) transplantation from a fully compatible donor sibling for the prevention and treatment of GvHD.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000245-55 Sponsor Protocol Number: AGO-GYN 7 Start Date*: 2008-06-24
    Sponsor Name:GYN Research GmbH
    Full Title: Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
    Medical condition: Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001008-37 Sponsor Protocol Number: Bab1 Start Date*: 2005-11-01
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022653-41 Sponsor Protocol Number: INT52/10 Start Date*: 2010-11-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder.
    Medical condition: Muscle-invasive transitional cell carcinoma of the bladder at clinical stage T>/=2N0.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005084 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002330-23 Sponsor Protocol Number: 9794 Start Date*: 2017-11-24
    Sponsor Name:University hospital of Montpellier
    Full Title: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY
    Medical condition: The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036706 Primary liver cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005248-81 Sponsor Protocol Number: INT0111 Start Date*: 2012-01-31
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Differentiated thyroid cancer: metabolic radiotherapy with high activity of radioiodine calculated by individual pre-therapy dosimetry
    Medical condition: Patients bearing differentiated thyroid carcinoma with distant metastases, candidated to metabolic radiotherapy after surgery or repetition of same therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002096-14 Sponsor Protocol Number: MF115 Start Date*: 2015-08-28
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Examine whether treatment with methylphenidate facilitates work rehabilitation for persons with long-term pain and mental fatigue after traumatic brain injury.
    Medical condition: Long-term pain and mental fatigue after traumatic brain injury and work rehabilitation.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004653-24 Sponsor Protocol Number: ARBAS041218 Start Date*: 2020-06-15
    Sponsor Name:Odense Universitets Hospital
    Full Title: Impact of an Angiotensin Receptor Blocker in Aortic Stenosis – A Randomized Controlled Trial
    Medical condition: Aortic valve stenosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002918 Aortic valve stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003529-13 Sponsor Protocol Number: 010617 Start Date*: 2017-10-19
    Sponsor Name:Thomas Benfield
    Full Title: Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacterermia: A randomized, non-blinded, non-inferiority interventional study
    Medical condition: Staphylococcus aureus bacteremia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004361-40 Sponsor Protocol Number: 2013/CHU/12 Start Date*: 2020-12-18
    Sponsor Name:CHU de la Réunion
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001145-40 Sponsor Protocol Number: P17-03 Start Date*: 2019-11-06
    Sponsor Name:Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts
    Full Title: French prospective open label phase II randomized non-comparative study of SC tocilizumab associated with IV pulse steroid versus IV pulse steroid alone for the treatment of acute anterior ischemic...
    Medical condition: Giant cell arteritis, acute anterior ischemic optic neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10043207 Temporal arteritis PT
    20.1 10015919 - Eye disorders 10030924 Optic ischaemic neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001300-22 Sponsor Protocol Number: PHRCI/2013/MV-001 Start Date*: 2014-12-17
    Sponsor Name:CHU de Nîmes
    Full Title: Evaluation de trois types d’infiltrations dans le cadre du traitement des épicondylalgies latérales : Leukocyte – Platelet Rich Plasma (L-PRP) versus Toxine botulique de type A (Xeomin®, MERZ) vers...
    Medical condition: epicondylitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10014971 Epicondylitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021898-36 Sponsor Protocol Number: INT 38/10 Start Date*: 2010-10-20
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment.
    Medical condition: Patients with metastatic germ-cell tumors failing first-line treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043302 LLT
    9.1 10061378 LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020375-24 Sponsor Protocol Number: 2010 - 020375 - 24 Start Date*: 2010-08-11
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Sorafenib in recurrent and/or metastatic salivary gland carcinomas
    Medical condition: advanced/metastatic disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029104 SOC
    9.1 10029105 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 17:30:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA